Want to see ORIC full AI Analyst Report?
ORIC Stock Chart & Stats
$12.10
-$0.08(-0.66%)
At close: 4:00 PM EDT
$12.10
-$0.08(-0.66%)
Day’s Range― - ―
52-Week Range$7.23 - $14.93
Previous Close$11.8
Volume1.71M
Average Volume (3M)1.65M
Market Cap
$1.17B
Enterprise Value$1.06K
Total Cash (Recent Filing)$281.93M
Total Debt (Recent Filing)$3.30M
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Aug 06, 2026EPS Estimate
-0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.44
Shares Outstanding103,517,560
10 Day Avg. Volume1,549,507
30 Day Avg. Volume1,650,377
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)1.87
Price to Sales (P/S)0.00
P/FCF Ratio-6.30
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$19.67Price Target Upside62.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-1.47
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetORIC’s near-zero debt and sizable equity provide durable financial flexibility for a clinical-stage biotech. Low leverage reduces bankruptcy risk and allows management to fund R&D spending and milestone-driven trials without immediate solvency pressure, supporting multi-quarter program execution.
Enhanced Equity-compensation Framework For HiringExpanding inducement equity and formalizing equity plans is a structural improvement for talent acquisition and integration of potential deals. This increases ORIC’s ability to attract senior scientists and business development hires, strengthening long-term pipeline execution and post-deal retention capacity.
Focused Oncology R&D StrategyA clear focus on overcoming cancer resistance targets a persistent, high-unmet-need market and creates potential for differentiated, durable therapeutics. Specialization improves ability to build scientific expertise, partnerships, and targeted trial designs that support sustainable drug development progress.
Bears Say
No Revenue; Widening Net LossesORIC’s lack of product revenue and materially larger net losses reflect continued pre-revenue status and rising R&D spend. Over the medium term this increases dependence on financing and heightens execution risk: trial setbacks or slower enrollment directly extend time to self-sustaining revenues.
Accelerating Negative Cash FlowConsistently negative operating and free cash flow at large and accelerating magnitudes creates persistent funding needs. This constrains the company’s ability to expand programs organically, increases reliance on external capital, and elevates the probability of dilution or constrained program pacing over months.
Structural Dilution Risk From Equity-based FundingWhile enabling recruitment, larger equity reserves and inducement plans increase the structural likelihood of share issuance as a financing and retention tool. Combined with ongoing cash burn and no revenue, this raises durable dilution risk for existing shareholders and can erode per-share economics over time.
Oric Pharmaceuticals News
ORIC FAQ
What was Oric Pharmaceuticals Inc’s price range in the past 12 months?
Oric Pharmaceuticals Inc lowest stock price was $7.23 and its highest was $14.93 in the past 12 months.
What is Oric Pharmaceuticals Inc’s market cap?
Oric Pharmaceuticals Inc’s market cap is $1.17B.
When is Oric Pharmaceuticals Inc’s upcoming earnings report date?
Oric Pharmaceuticals Inc’s upcoming earnings report date is Aug 06, 2026 which is in 6 days.
How were Oric Pharmaceuticals Inc’s earnings last quarter?
Oric Pharmaceuticals Inc released its earnings results on May 04, 2026. The company reported -$0.34 earnings per share for the quarter, missing the consensus estimate of -$0.321 by -$0.019.
Is Oric Pharmaceuticals Inc overvalued?
According to Wall Street analysts Oric Pharmaceuticals Inc’s price is currently Undervalued.
Does Oric Pharmaceuticals Inc pay dividends?
Oric Pharmaceuticals Inc does not currently pay dividends.
What is Oric Pharmaceuticals Inc’s EPS estimate?
Oric Pharmaceuticals Inc’s EPS estimate is -0.36.
How many shares outstanding does Oric Pharmaceuticals Inc have?
Oric Pharmaceuticals Inc has 103,517,560 shares outstanding.
What happened to Oric Pharmaceuticals Inc’s price movement after its last earnings report?
Oric Pharmaceuticals Inc reported an EPS of -$0.34 in its last earnings report, missing expectations of -$0.321. Following the earnings report the stock price went down -0.623%.
Which hedge fund is a major shareholder of Oric Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in ORIC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Oric Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.67 (62.53% Upside)
$19.67 (62.53% Upside)
Blogger Sentiment
Neutral
ORIC Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 41.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 6.3%
Last 30 Days ▼ 6.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
3.15%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
79.84%
Trailing 12-Months
Company Description
Oric Pharmaceuticals Inc
ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States. The company's pipeline includes several key clinical-stage drug candidates. ORIC-533 is an oral small molecule designed to inhibit CD73, addressing resistance to both chemotherapy and immunotherapy. Another candidate, ORIC-944, is an allosteric inhibitor targeting the polycomb repressive complex 2, specifically for the treatment of prostate cancer. Furthermore, ORIC-114 is a brain-penetrant, orally administered, irreversible inhibitor crafted to precisely target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), demonstrating high potency against exon 20 insertion mutations. Beyond these advanced programs, ORIC Pharmaceuticals is also cultivating multiple early-stage precision medicines aimed at other mechanisms of cancer resistance. The company has established partnerships, including a licensing and collaboration agreement with Voronoi Inc., and a licensing agreement with Mirati Therapeutics, Inc. ORIC Pharmaceuticals was founded in 2014 and maintains its headquarters in South San Francisco, California.
ORIC Stock 12 Month Forecast
Average Price Target
$19.67
▲(62.53% Upside)
Technical Analysis
Spyre Therapeutics
―
Trevi Therapeutics
―
Praxis Precision Medicines
―
Pharming Group
―
Prime Medicine, Inc.
―
Ownership Overview
1.04% Insiders
15.46% Mutual Funds
0.11% Other Institutional Investors
69.58% Public Companies and
Individual Investors